

Supplementary Table 1. Summary of washout time and duration of next DMT after natalizumab discontinuation (N=1582).

First DMT used after natalizumab discontinuation	n (%)	Washout time, months ^a		Duration of DMT use, months ^b	
		Mean (SD)	Median (min, max)	Mean (SD)	Median (min, max)
Injectable therapies	296 (18.7)	3.9 (6.12)	1.8 (0, 52.7)	21.8 (18.86)	15.4 (0, 95.5)
Interferon beta-1a IM	44 (2.8)	7.2 (10.43)	2.9 (0, 52.7)	23.6 (19.82)	20.1 (0.4, 85.2)
Interferon beta-1a SC	68 (4.3)	4.0 (6.27)	1.9 (0, 34.8)	22.3 (19.24)	17.1 (1.1, 84.8)
Interferon beta-1b	44 (2.8)	2.4 (3.83)	1.1 (0, 21.3)	22.2 (19.63)	14.6 (2.2, 95.5)
Glatiramer acetate	140 (8.8)	3.2 (4.21)	1.8 (0, 24.7)	20.9 (18.27)	14.2 (0, 85.8)
Oral therapies	1118 (70.7)	4.1 (5.51)	2.7 (0, 72.5)	27.8 (16.46)	26.1 (0, 83.4)
Fingolimod	915 (57.8)	3.9 (4.74)	2.8 (0, 52.5)	30.1 (16.64)	28.3 (0, 83.4)
Teriflunomide	26 (1.6)	7.0 (7.45)	5.1 (0.2, 34.8)	17.0 (9.81)	16.3 (3.3, 32.8)
Dimethyl fumarate	177 (11.2)	4.5 (8.16)	2.0 (0, 72.5)	17.1 (10.31)	17.0 (0, 41.5)
Alemtuzumab	57 (3.6)	5.2 (4.12)	4.3 (0.4, 21.1)	11.2 (12.86)	10.4 (0, 62.6)
Immunosuppressants ^c	111 (7.0)	6.4 (6.44)	4.0 (0, 31.7)	17.5 (16.45)	12.7 (0, 66.2)

DMT: disease-modifying therapy; IM: intramuscular; SC: subcutaneous; SD: standard deviation.

A 28-day month was used for this analysis.

^aDMT start is reported as month and year, not as a specific date. If the year and month of subsequent DMT start and natalizumab discontinuation were the same, washout time was recorded as 1 day.

^bIf DMT use was ongoing, the last visit date was included as the end date.

^cIncludes mitoxantrone (n=~~39~~41), azathioprine (n=~~21~~22), cyclophosphamide (n=~~24~~25), cyclosporine (n=1), rituximab (n=~~12~~16), methotrexate (n=~~2~~3), and cladribine (n=3).